Complix to Present at BioCapital Europe 2014

Description

Complix to Present at BioCapital EuropeComplix to Present at BioCapital Europe 2014 PR Newswire HASSELT, Belgium, March 26, 2014 Complix, a biopharmaceutical company focused on the discovery and development of Cell Penetrating Alphabodies™ (CPABs), a unique class of protein therapeutics that are active against intracellular disease targets, announces that its CEO Dr Mark

Informations

• Publié par: complix
• Publié le: 26 mars 2014
• Nombre de lectures: 2
• Langue: English

Extrait

Complix to Present at BioCapital Europe 2014

PR Newswire

HASSELT, Belgium, March 26, 2014

Complix, a biopharmaceutical company focused on the discovery and development of Cell Penetrating Alphabodies™ (CPABs), a unique class of protein therapeutics that are active against intracellular disease targets, announces that its CEO Dr Mark Vaeck will present tomorrow at BioCapital Europe 2014 in Amsterdam, the Netherlands (March 27th). Details of the presentation are listed below.

Dr Vaeck will give an update on Complix and its recent progress in developing CPABs against intracellular targets to generate novel first-in-class therapeutics.

Alphabodies represent a transformative therapeutic development platform with the capacity to address a vast number of disease targets that are currently considered "undruggable" by the two main classes of therapeutic drugs: small chemical drugs and therapeutic antibodies. CPABs in particular, with their ability to act on intracellular protein targets, represent a major medical and commercial opportunity. It is estimated that there are more than 1000 intracellular disease targets which are known to be involved in important disease processes, but are currently undruggable.

Complix' CPABs have the unique capacity to enter cells effectively and modulate intracellular protein-to-protein interactions (PPIs). The Company has generated compelling data with Complix' lead CPAB program against the intracellular cancer target MCL-1. MCL-1 is an important regulator of cellular apoptosis and is often over-expressed in cancer cells and prevents them from dying.

Dr Mark Vaeck, CEO of Complix, comments: "Since the closing of our €12 million Series B round last summer, we have made excellent progress in advancing our lead oncology anti-MCL-1 program, showing that CPABs can interfere with this important cancer target to induce cellular apoptosis. Highly specific and safe therapeutics that can effectively address intracellular disease targets are a major drug development opportunity. We believe our novel CPAB therapeutics are a breakthrough in drug development and represent what should become the next generation of therapeutic proteins."

Details of the presentation are as follow:

Presentation by Dr Mark Vaeck, CEO of Complix NV
Time: Thursday, March 27th 2014; 2.20pm CET
Location: Amsterdam
Venue: Sofitel Amsterdam the Grand; Alderman's  Chamber

About  Complix

Complix is a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies™, mainly focused on oncology and autoimmune diseases.

Alphabodies are a revolutionary class of protein therapeutics that have the potential to address a wide range of disease targets, in particular intracellular targets that are considered undruggable by current drug formats, such as antibodies or small chemicals. Complix' current R&D efforts are mainly focused on the development of Cell-Penetrating Alphabodies (CPABs) that have the unique capacity to enter tumor cells effectively and selectively modulate intracellular protein-to-protein interactions (PPIs) which play a key role in the initiation and progression of cancer.

Complix has established a strong intellectual property position protecting the Alphabody™ platform and its emerging product portfolio through the filing of multiple broad patent applications. Alphabody-based therapeutics are independent of antibody-based patent claims and offer a unique freedom-to-operate position.

Since its founding in 2008 Complix has raised a total of €26 million in funding (approximately US$ 34 million), including a €12 million B round in June 2013 and a €7 million Series A equity round in 2010.

Contacts
Complix NV
Dr. Mark Vaeck, CEO
[phone]